Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Ness, Daniel ^a   Ren, Zhao ^a   Gardai, Shyra ^a   Sharpnack, Douglas ^c   Johnson, Victor J ^d   Brennan, Richard J ^b   Brigham, Elizabeth F ^a   Olaharski, Andrew J ^a  

^a ELAN PHARMACEUTICALS   (United States)

^b Thomson Reuters   (United States)

^c Vet Path Services Inc   (United States)

^d BRT Burleson Research Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LEUCINE RICH REPEAT KINASE 2; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SOMATOMEDIN; THIOREDOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; HISTOPATHOLOGY; HOMEOSTASIS; IMMUNE RESPONSE; IMMUNOLOGY; INFLUENZA; KIDNEY TUBULE CELL; KIDNEY TUBULE DAMAGE; LRRK2 GENE; MALE; METABOLISM; NONHUMAN; PNEUMOCOCCAL INFECTION; RAT; SPLEEN CELL; WEIGHT GAIN;

ANIMALS; ANTIBODIES, VIRAL; BLOOD PROTEINS; EPITHELIAL CELLS; GENE KNOCKOUT TECHNIQUES; GENE REGULATORY NETWORKS; HOMEOSTASIS; IMMUNITY, HUMORAL; IMMUNOPHENOTYPING; KIDNEY TUBULES; MALE; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; PROTEIN-SERINE-THREONINE KINASES; RATS; STREPTOCOCCUS PNEUMONIAE; WEIGHT GAIN;

ANIMALIA; ORTHOMYXOVIRIDAE; RATTUS; STREPTOCOCCUS PNEUMONIAE;

EID: 84879129926     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066164     Document Type: Article

References (46)

1. Lees AJ, Hardy J, Revesz T, (2009) Parkinson's disease. Lancet 373: 2055-2066.
2. Dawson TM, Moore DJ, West AB, (2009) Revelations and revolutions in the understanding of Parkinson's disease. Biochim Biophys Acta 1792: 585-586.
3. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601-607.
4. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 595-600.
5. Cookson MR, (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 11: 791-797.
6. Gaig C, Ezquerra M, Marti MJ, Munoz E, Valldeoriola F, et al. (2006) LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 63: 377-382.
7. Greggio E, Cookson MR (2009) Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 1.
8. Gehrke S, Imai Y, Sokol N, Lu B, (2010) Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466: 637-641.
9. Lichtenberg M, Mansilla A, Zecchini VR, Fleming A, Rubinsztein DC, (2011) The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell Death Dis 2: e196.
10. Waxman EA, Covy JP, Bukh I, Li X, Dawson TM, et al. (2009) Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions. J Neuropathol Exp Neurol 68: 785-796.
11. Dodson MW, Zhang T, Jiang C, Chen S, Guo M, (2012) Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet 21: 1350-1363.
12. Plowey ED, Cherra SJ 3rd, Liu YJ, Chu CT (2008) Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem 105: 1048-1056.
13. Ramonet D, Daher JP, Lin BM, Stafa K, Kim J, et al. (2011) Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 6: e18568.
14. Gomez-Suaga P, Luzon-Toro B, Churamani D, Zhang L, Bloor-Young D, et al. (2012) Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet 21: 511-525.
15. Wang X, Yan MH, Fujioka H, Liu J, Wilson-Delfosse A, et al. (2012) LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 21: 1931-1944.
16. Chen CY, Weng YH, Chien KY, Lin KJ, Yeh TH, et al. (2012) (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ 19: 1623-1633.
17. Ho CC, Rideout HJ, Ribe E, Troy CM, Dauer WT, (2009) The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J Neurosci 29: 1011-1016.
18. Herzig MC, Kolly C, Persohn E, Theil D, Schweizer T, et al. (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet 20: 4209-4223.
19. Hinkle KM, Yue M, Behrouz B, Dachsel JC, Lincoln SJ, et al. (2012) LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol Neurodegener 7: 25.
20. Tong Y, Yamaguchi H, Giaime E, Boyle S, Kopan R, et al. (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 107: 9879-9884.
21. Greggio E, Civiero L, Bisaglia M, Bubacco L, (2012) Parkinson's disease and immune system: is the culprit LRRKing in the periphery? J Neuroinflammation 9: 94.
22. Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, et al. (2012) LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 32: 1602-1611.
23. Gillardon F, Schmid R, Draheim H, (2012) Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 208: 41-48.
24. Kim B, Yang MS, Choi D, Kim JH, Kim HS, et al. (2012) Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One 7: e34693.
25. Nikolsky Y, Nikolskaya T, Bugrim A, (2005) Biological networks and analysis of experimental data in drug discovery. Drug Discov Today 10: 653-662.
26. Ekins S, Bugrim A, Nikolsky Y, Nikolskaya T, Gad SC (2010) Systems Biology: Applications in Drug Discovery. Pharmaceutical Sciences Encyclopedia: John Wiley & Sons, Inc.
27. Myshkin E, Brennan R, Khasanova T, Sitnik T, Serebriyskaya T, et al. (2012) Prediction of organ toxicity endpoints by QSAR modeling based on precise chemical-histopathology annotations. Chem Biol Drug Des 80: 406-416.
28. Dezso Z, Bugrim A, Brennan RJ, Nikolsky Y, Nikolskaya T (2009) Statistical Methods for Functional Analysis of 'Omics Experimental Data. In: Choudhuri S, Carlson DB, editors. Genomics: Fundamentals and Applications. New York: Informa Healthcare. 269-288.
29. Das SK, Sharma NK, Hasstedt SJ, Mondal AK, Ma L, et al. (2011) An integrative genomics approach identifies activation of thioredoxin/thioredoxin reductase-1-mediated oxidative stress defense pathway and inhibition of angiogenesis in obese nondiabetic human subjects. J Clin Endocrinol Metab 96: E1308-1313.
30. Blouet C, Schwartz GJ, (2011) Nutrient-sensing hypothalamic TXNIP links nutrient excess to energy imbalance in mice. J Neurosci 31: 6019-6027.
31. Ikegami H, Ono M, Fujisawa T, Hiromine Y, Kawabata Y, et al. (2008) Molecular scanning of the gene for thioredoxin, an antioxidative and antiapoptotic protein, and genetic susceptibility to type 1 diabetes. Ann N Y Acad Sci 1150: 103-105.
32. Inzelberg R, Cohen OS, Aharon-Peretz J, Schlesinger I, Gershoni-Baruch R, et al. (2012) The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology 78: 781-786.
33. Deng X, Dzamko N, Prescott A, Davies P, Liu Q, et al. (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol 7: 203-205.
34. Mellor HR, Bell AR, Valentin JP, Roberts RR, (2011) Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol Sci 120: 14-32.
35. Boverhof DR, Chamberlain MP, Elcombe CR, Gonzalez FJ, Heflich RH, et al. (2011) Transgenic animal models in toxicology: historical perspectives and future outlook. Toxicol Sci 121: 207-233.
36. Nikonova EV, Xiong Y, Tanis KQ, Dawson VL, Vogel RL, et al. (2012) Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity. Hum Mol Genet 21: 163-174.
37. Blouet C, Liu SM, Jo YH, Chua S, Schwartz GJ, (2012) TXNIP in Agrp neurons regulates adiposity, energy expenditure, and central leptin sensitivity. J Neurosci 32: 9870-9877.
38. Huh JY, Kim Y, Jeong J, Park J, Kim I, et al. (2012) Peroxiredoxin 3 is a key molecule regulating adipocyte oxidative stress, mitochondrial biogenesis, and adipokine expression. Antioxid Redox Signal 16: 229-243.
39. Angeles DC, Gan BH, Onstead L, Zhao Y, Lim KL, et al. (2011) Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum Mutat 32: 1390-1397.
40. Tong Y, Giaime E, Yamaguchi H, Ichimura T, Liu Y, et al. (2012) Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener 7: 2.
41. Wang EJ, Snyder RD, Fielden MR, Smith RJ, Gu YZ, (2008) Validation of putative genomic biomarkers of nephrotoxicity in rats. Toxicology 246: 91-100.
42. Tsigou E, Psallida V, Demponeras C, Boutzouka E, Baltopoulos G, (2013) Role of new biomarkers: functional and structural damage. Crit Care Res Pract 2013: 361078.
43. Bravo-San Pedro JM, Niso-Santano M, Gomez-Sanchez R, Pizarro-Estrella E, Aiastui-Pujana A, et al. (2012) The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway. Cell Mol Life Sci.
44. Gardet A, Benita Y, Li C, Sands BE, Ballester I, et al. (2010) LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol 185: 5577-5585.
45. Liu Z, Lee J, Krummey S, Lu W, Cai H, et al. (2011) The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol 12: 1063-1070.
46. Danoy P, Pryce K, Hadler J, Bradbury LA, Farrar C, et al. (2010) Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet 6: e1001195.